$CNO

Bhojwani Gary C. sold $4.4M of CNO

Bhojwani Gary C. (Chief Executive Officer) sold 86,048 shares of CNO Financial Group, Inc. (CNO) at an average of $51.48 ($51.48–$51.48, $4.43M total) across 2 trades on 2026-06-30 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Bhojwani Gary C.
Published Jul 1, 2026, 8:10 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 1, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CNO
Neutral
medium confidence
Mentioned
$CNO
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CNONeutralLow
01

Why it matters

The newest concrete fact is the CEO’s $4.43M open-market sale executed under a 10b5-1 plan; this can influence short-term sentiment but is less likely to change fundamentals immediately.

02

Market read

Traders may monitor for follow-on insider activity, but the 10b5-1 framing typically limits interpretive weight.

03

What to watch

The filing does not disclose reasons for the sale, and the CEO’s remaining holdings (174,264 shares after) may still indicate continued long-term exposure.

Relevance 5/10Novelty 5/10Timing: new Form 4 filed 2026-07-01 (covering 2026-06-30 sale)

Background

The article is a SEC Form 4 insider transaction disclosure for CNO Financial Group, Inc. (CNO).

Company-level read

Ticker impact

$CNONeutralMedium confidence
Context

CNO CEO Gary C. Bhojwani sold $4.43M of CNO shares in an open-market transaction under a pre-arranged 10b5-1 plan on 2026-06-30.

Expected impact

Likely limited immediate price impact; any effect is more sentiment/positioning than fundamentals.

Evidence & confidence

The filing is a primary-source Form 4 showing a sizable sale ($4.43M) while explicitly stating a pre-arranged 10b5-1 plan, which typically dampens interpretive value versus discretionary selling.

Market effects

Minimal; this is company-specific insider activity with no sector-wide regulatory or earnings signal.

None indicated; US-listed insurer insider transaction only.

None indicated; no cross-border deal, regulation, or macro linkage described.

Counterpoint

Because the sale is executed under a pre-arranged 10b5-1 plan, it may reflect routine liquidity/compensation rather than a bearish view on CNO’s prospects.

Key entities

  • CNO Financial Group, Inc.

    Subject of the Form 4 insider transaction; CEO sold 86,048 shares for ~$4.43M.

  • Gary C. Bhojwani

    CNO CEO and director who executed the open-market sale under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CNOMed

California Nanotechnologies Posts 28% Revenue Growth in Q1 FY2027 as Nuclear Pivot Takes Hold

California Nanotechnologies (TSXV:CNO) reported Q1 FY2027 revenue of $917,854, up 28% from $716,553 a year earlier, for the quarter ended May 31, 2026. Adjusted EBITDA loss narrowed to $129,031 from $152,707, while net loss was $449,598. The company attributes growth to customer diversification and a nuclear supply-chain pivot tied to initial SMR component purchase orders.

$CNOHighAI 9/10

CNO Financial (CNO) Q2 2026 Earnings Call Transcript

CNO Financial Group (NYSE:CNO) reported Q2 2026 operating EPS of $1.26, up 45% year over year, and net operating income of $119.5 million. Total new annualized premiums rose 7% to a record. Full-year EPS guidance was raised to $4.60 to $4.80. The company also repurchased $60 million of shares.

$CNOMed

CNO Financial posts insurance income gain on 16-quarter sales streak

CNO Financial Group reported Q2 2026 sales growth for a 16th consecutive quarter. Insurance policy income rose to $680.7 million from $651.3 million a year earlier, and net income increased to $125.9 million, or $1.33 per diluted share, from $91.8 million, or $0.91. CNO raised full-year 2026 operating EPS guidance by 8% at the midpoint and estimated RBC at 377% as of June 30.

$CNOMed

CNO Financial Group’s (NYSE:CNO) Q2 CY2026 Sales Beat Estimates

Insurance services company CNO Financial Group (NYSE: CNO) announced better-than-expected revenue in Q2 CY2026, with sales up 34.6% year on year to $1.29 billion. Its GAAP profit of $1.33 per share was 36.4% above analysts’ consensus estimates. Is now the time to buy CNO Financial Group? Find out by accessing our full research report, it’s free.

$CNOLow

CNO Financial Group, Inc. (CNO): Results of Operations and Financial Condition

CNO Financial Group, Inc. (CNO) filed an SEC Form 8-K — Results of Operations and Financial Condition. News For Immediate Release CNO Financial Group Reports Second Quarter 2026 Results Carmel, Ind., July 30, 2026 - CNO Financial Group, Inc. (NYSE: CNO) today reported its second quarter 2026 financial results: • Strong execution and momentum continues; Raising 2026 operating earni